Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease is proud to announce a strategic collaboration with SciLifeLab to advance translational proteomics and accelerate biomarker discovery.
Health Technology Insights: Care Resource Opens New Health Center in Little Havana
The partnership brings together Alamar’s NULISA technology and ARGO HT system—offering ultra-sensitive, multiplexed protein analysis from biofluids—with SciLifeLab’s Proteomics Capabilities and its extensive data resources, including the Human Protein Atlas, a research program that maps the human proteome. Together, the organizations aim to deepen understanding of disease biology and drive development of early diagnostic tools.
“We are thrilled to partner with SciLifeLab in this important work,” Dr. Yuling Luo, Chairman, Founder & CEO of Alamar Biosciences stated. “Our combined technologies will provide comprehensive data on protein expression and localization, which will be instrumental in validating signatures discovered using the NULISA platform.”
Health Technology Insights: Cizzle Bio Lung Test May Save Medicare $518Million Annually
“SciLifeLab’s expertise in affinity proteomics, combined with our national infrastructure and partnership with National Genomics Infrastructure, makes this a natural environment for a cutting-edge technology like the ARGO HT System,” said Professor Jochen Schwenk, SciLifeLab Group Leader and Platform Scientific Director of Proteomics. “We look forward to enabling new levels of sensitivity, scalability, and integration in biomarker discovery.”
Health Technology Insights: Perimeter and Intermountain Study AI, OCT to Cut Reoperations
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
